Other OTC - Delayed Quote USD

PixarBio Corporation (PXRB)

0.0000 0.0000 (0.00%)
At close: June 27 at 3:17 PM EDT
Loading Chart for PXRB
DELL
  • Previous Close 0.0000
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.0000
  • Volume 100
  • Avg. Volume 100
  • Market Cap (intraday) 81
  • Beta (5Y Monthly) -54.42
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1890
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

PixarBio Corporation, a specialty pharmaceutical/biotechnology company, focuses on the pre-clinical and clinical development of neurological drug delivery systems for post-operative pain. The company researches and develops delivery systems for drugs, devices, or biologics to treat pain, epilepsy, epilepsy, Parkinson's disease, and spinal cord injury. Its principal product platform is NeuroRelease for the therapeutic release of non-opiate drugs for post-operative, acute, and chronic pain in pre-clinical models. The company was founded in 2014 and is based in Medford, Massachusetts.

www.pixarbio.com

30

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Related News

Performance Overview: PXRB

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PXRB
0.00%
MSCI WORLD
4.81%

1-Year Return

PXRB
--
MSCI WORLD
13.71%

3-Year Return

PXRB
--
MSCI WORLD
13.71%

5-Year Return

PXRB
--
MSCI WORLD
13.71%

Compare To: PXRB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PXRB

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    7.5k

  • Net Income Avi to Common (ttm)

    -12.19M

  • Diluted EPS (ttm)

    -0.1890

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    715.11k

  • Total Debt/Equity (mrq)

    32.66%

  • Levered Free Cash Flow (ttm)

    --

Company Insights: PXRB